Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Brief Summary: The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to very severe COPD.


Options:
A: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
B: Arm Label: NVA237 + indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 50 µg and indacaterol 150 µg | Arm Label: Placebo to NVA237 + indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to NVA237 and indacaterol 150 µg | Intervention Type: DRUG; Name: NVA237 50 µg and indacaterol 150 µg; Assigned to Arm(s): NVA237 + indacaterol | Intervention Type: DRUG; Name: Placebo to NVA237 and indacaterol 150 µg; Assigned to Arm(s): Placebo to NVA237 + indacaterol
C: Arm Label: Umeclidinium/vilanterol Arm; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/vilanterol, Drug: Placebo | Arm Label: Fluticasone propionate/salmeterol Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol, Drug: Placebo | Intervention Type: DRUG; Name: Umeclidinium/vilanterol; Assigned to Arm(s): Umeclidinium/vilanterol Arm | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm, Umeclidinium/vilanterol Arm
D: Arm Label: GFF MDI; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI | Arm Label: GP MDI; Type: EXPERIMENTAL; Interventions: Drug: GP MDI | Arm Label: FF MDI; Type: EXPERIMENTAL; Interventions: Drug: FF MDI | Arm Label: Open-label tiotropium bromide inhalation powder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDI | Intervention Type: DRUG; Name: GFF MDI; Assigned to Arm(s): GFF MDI | Intervention Type: DRUG; Name: GP MDI; Assigned to Arm(s): GP MDI | Intervention Type: DRUG; Name: FF MDI; Assigned to Arm(s): FF MDI | Intervention Type: DRUG; Name: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®); Assigned to Arm(s): Open-label tiotropium bromide inhalation powder | Intervention Type: DRUG; Name: Placebo MDI; Assigned to Arm(s): Placebo

Answer: D